Replenishable prevascularized cell encapsulation devices increase graft survival and function in the subcutaneous space

Beta cell replacement therapy (BCRT) for patients with type 1 diabetes (T1D) improves blood glucose regulation by replenishing the endogenous beta cells destroyed by autoimmune attack. Several limitations, including immune isolation, prevent this therapy from reaching its full potential. Cell encaps...

Descripción completa

Detalles Bibliográficos
Autores principales: Chendke, Gauree S., Kharbikar, Bhushan N., Ashe, Sudipta, Faleo, Gaetano, Sneddon, Julie B., Tang, Qizhi, Hebrok, Matthias, Desai, Tejal A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354771/
https://www.ncbi.nlm.nih.gov/pubmed/37476069
http://dx.doi.org/10.1002/btm2.10520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354771/
https://www.ncbi.nlm.nih.gov/pubmed/37476069
http://dx.doi.org/10.1002/btm2.10520

Ejemplares similares